BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate in patients who have predominately liver metastasis from neuroendocrine cancers. August 15, 2012 marks the date for the treatment of the first patient with intra-hepatic artery administration at Excel Diagnostics & Nuclear Oncology Center in Houston, Texas.
The clinical trial of Lutetium-177 (Lu-177) with Octreotate is the first in North America for neuroendocrine cancer patients. The trial began in September 2010 and represents a milestone in treatment options for carcinoid and NET (neuroendocrine tumor) cancer patients. The clinical trial is being conducted at Excel Diagnostics in Houston, Texas, and is a collaboration of BioSynthema, Inc. of St. Louis, Missouri, and Baylor College of Medicine, St. Luke’s Episcopal Hospital, and the RITA Foundation, all in Houston, Texas.
Lutetieum-177 radionuclide is one of the radioactive materials used in PRRT, peptide receptor radionuclide therapy, as is Y-90 (Yttrium-90). When labeled with somatostatin analogs such as Octreotate, these agents can be used for progressive neuroendocrine tumors that are resistant to octreotide/interferon treatment or chemotherapy. LU-177 Octreotate has been used in Europe for over a decade and is also available in Australia, India, and just recently began in Singapore. It has a shorter path length in the tissue than Y-90 has and is less toxic to both the kidneys and bone marrow. During the past 17 years, studies of radio-peptide therapy for various neuroendocrine cancers have shown good clinical and radiological results with minimal side effects.
Ebrahim S. Delpassand, MD, principal investigator for the U.S. program, said of the new FDA approval, “We are extremely pleased regarding the recent approval of FDA for this preferential administration of Lu-177 Octreotate in patients who have predominantly liver metastases. The majority of NET patients referred for PRRT have significant liver involvement and this method of administration will expose the cancer lesions to the highest concentration of the medication. I anticipate the effectiveness for treating liver lesions with this method of administration will be 4 to 5 times higher than systemic intravenous administration. This is definitely an exciting milestone in the fight against neuroendocrine cancers.”
For further information regarding this treatment, contact Ms. Susan Cork, clinical coordinator of the project, at 713-341-3203 or email@example.com.
To read our blog about the FDA’s 2010 approval of the clinical trial, CLICK HERE.